The behavioral toxicity of monoamine oxidase-inhibiting antidepressants.
D000818:Animals; D000929:Antidepressive Agents, Tricyclic / Q000009:adverse effects; D001519:Behavior / Q000187:drug effects*; D001522:Behavior, Animal / Q000187:drug effects; D003913:Dextroamphetamine / Q000009:adverse effects; D006801:Humans; D006834:Hydrazines / Q000009:adverse effects; D007490:Iproniazid / Q000009:adverse effects; D007520:Isocarboxazid / Q000009:adverse effects; D007980:Levodopa / Q000009:adverse effects; D008094:Lithium / Q000009:adverse effects; D008996:Monoamine Oxidase Inhibitors / Q000009:adverse effects*; D009526:Nialamide / Q000009:adverse effects; D010293:Pargyline / Q000009:adverse effects; D010624:Phenelzine / Q000009:adverse effects; D011344:Procarbazine / Q000009:adverse effects; D051381:Rats; D014191:Tranylcypromine / Q000009:adverse effects; D014364:Tryptophan / Q000009:adverse effects
D000929:Antidepressive Agents, Tricyclic; D006834:Hydrazines; D008996:Monoamine Oxidase Inhibitors; D007520:Isocarboxazid; D011344:Procarbazine; D014191:Tranylcypromine; D007980:Levodopa; D014364:Tryptophan; D008094:Lithium; D010293:Pargyline; D007490:Iproniazid; D010624:Phenelzine; D009526:Nialamide; D003913:Dextroamphetamine